Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.